|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A comprehensive analysis on the significance of eIF4E translation factor in the clinical picture of leukemia arises, therefore, as a compelling need.
|
29527921 |
2018 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia.
|
27094611 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings offer a preclinical rationale to explore broadening the clinical evaluation of ribavirin, currently being tested in patients with eIF4E-overexpressing leukemia, as a strategy to treat solid tumors such as metastatic breast cancer.
|
25608710 |
2015 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
|
26317515 |
2015 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Importantly, ICG-001, regardless of CBP mutational status and chromosomal aberration, leads to eradication of drug-resistant primary leukemia in combination with conventional therapy in vitro and significantly prolongs the survival of NOD/SCID mice engrafted with primary ALL.
|
23728349 |
2014 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, murine myeloid progenitor cells carrying an Mll-CBP knock-in allele that mimics human t(11;16) leukaemia show a severe radioresistant DNA synthesis phenotype.
|
20818375 |
2010 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results imply that multiple Myb domains influence its interaction with CBP/p300, highlight the importance of this interaction for myeloid transformation, and suggest an approach for molecular targeting of Myb in leukemia.
|
19737967 |
2009 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This competitive mechanism of eIF4E regulation is disrupted in a subset of leukemias, where HOXA9 displaces PRH from eIF4E, thereby contributing to eIF4E's dysregulation.
|
15657436 |
2005 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Characterization of genomic breakpoints in MLL and CBP in leukemia patients with t(11;16).
|
15334549 |
2004 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In support of this hypothesis' at least three fusions associated with leukaemias and involving transcriptional co-activators CBP and p300 have been recently cloned.
|
11355923 |
2001 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Because 11q23 translocations involving MLL and t(8;16) involving MOZ and CBP have been reported in therapy-related leukemias, both the MLL and CBP genes may be targets for topoisomerase II inhibitors.
|
9290955 |
1997 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both fusion products retain the histone acetyltransferase domain of CBP and may lead to leukemia by promoting histone acetylation of genomic regions targeted by the MLL AT-hooks, leading to transcriptional deregulation via aberrant chromatin organization.
|
9238046 |
1997 |